Time trends in the prescription of sodium-glucose co-transporter-2 inhibitors based on a claims database in Japan from 2014 to 2022: expanded use in older adults, those with comorbidities, and those potentially initiating diabetes treatment
{{output}}
Background/objectives: Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) were initially prescribed with caution due to potential adverse effects, including hypoglycemia, ketoacidosis, dehydration, and genital or urinary tract i... ...
